Advertisement

EBV as the ‘gluten of MS’ hypothesis: Bypassing autoimmunity

      Abstract

      The EBV as the ‘gluten of MS’ hypothesis discussed by Drosu et al. in a recent Editorial envisages the existence of similar mechanisms leading to celiac disease and multiple sclerosis, such as induction of immunity against an ubiquitous exogenous antigen - gluten and EBV, respectively - and subsequent development of autoimmunity that is maintained by persistence of the initial trigger. While this hypothesis provides the rationale for treating MS with antivirals to lower EBV load, it can be misleading when trying to translate concepts of T cell-B cell interaction and autoimmunity development in celiac disease to multiple sclerosis. Here, we propose that EBV might act as the driver of multiple sclerosis without involving autoimmunity.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Abadie V.
        • Kim S.M.
        • Lejeune T.
        • et al.
        IL-15, gluten and HLA-DQ8 drive tissue destruction in coeliac disease.
        Nature. 2020; 578: 600-604https://doi.org/10.1038/s41586-020-2003-8
        • Angelini D.F.
        • Serafini B.
        • Piras E.
        • et al.
        Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis.
        PLoS Pathog. 2013; 9e1003220https://doi.org/10.1371/journal.ppat.1003220
        • Bjornevik K.
        • Cortese M.
        • Healy B.C.
        • et al.
        Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis.
        Science. 2022; 375: 296-301https://doi.org/10.1126/science.abj8222
        • Bronge M.
        • Högelin K.A.
        • Thomas O.G.
        • et al.
        Identification of four novel T cell autoantigens and personal autoreactive profiles in multiple sclerosis.
        Sci. Adv. 2022; 8: eabn1823https://doi.org/10.1126/sciadv.abn1823
        • Brynedal B.
        • Duvefelt K.
        • Jonasdottir G.
        • et al.
        HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis.
        PLoS One. 2007; 2: e664https://doi.org/10.1371/journal.pone.0000664
        • Carmena Moratalla A.
        • Carpentier Solorio Y.
        • Lemaitre F.
        • et al.
        Stress signal ULBP4, an NKG2D ligand, is upregulated in multiple sclerosis and shapes CD8+ T-cell behaviors.
        Neurol. Neuroimmunol. Neuroinflamm. 2022; 9: e1119https://doi.org/10.1212/NXI.0000000000001119
        • Drosu N.
        • Giovannoni G.
        • Lechner-Scott J.
        • et al.
        EBV as the "gluten of MS" hypothesis provides a rationale for trialing antiviral therapies.
        Mult. Scler. Relat. Disord. 2022; 1104007https://doi.org/10.1016/j.msard.2022.104007
        • Drosu N.
        • Giovannoni G.
        • Pohl D.
        • et al.
        Probing the association between multiple sclerosis and Epstein Barr virus from a therapeutic perspective.
        Mult. Scler. Relat. Disord. 2021; 52103087https://doi.org/10.1016/j.msard.2021.103087.12
        • Hassani A.
        • Corboy J.R.
        • Al-Salam S.
        • Khan G.
        Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells.
        PLoS One. 2018; 13e0192109https://doi.org/10.1371/journal.pone.0192109
        • Hauser S.L.
        • Waubant E.
        • Arnold D.L.
        • et al.
        B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
        N. Engl. J. Med. 2008; 358: 676-688https://doi.org/10.1056/NEJMoa0706383
        • Hedström A.K.
        • Huang J.
        • Michel A.
        • et al.
        High levels of Epstein-Barr virus nuclear antigen-1-specific antibodies and infectious mononucleosis act both independently and synergistically to increase multiple sclerosis risk.
        Front. Neurol. 2020; 10: 1368https://doi.org/10.3389/fneur.2019.01368
        • Hohlfeld R.
        • Dornmair K.
        • Meinl E.
        • Wekerle H.
        The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research.
        Lancet Neurol. 2016; 15: 317-331https://doi.org/10.1016/S1474-4422(15)00313-0
        • Holmøy T.
        • Vartdal F.
        Cerebrospinal fluid T cells from multiple sclerosis patients recognize autologous Epstein-Barr virus-transformed B cells.
        J. Neurovirol. 2004; 10: 52-56https://doi.org/10.1080/13550280490261671
        • Iversen R.
        • Sollid L.M.
        Autoimmunity provoked by foreign antigens.
        Science. 2020; 368: 132-133https://doi.org/10.1126/science.aay3037
        • Jabri B.
        • Sollid L.M.
        T cells in celiac disease.
        J. Immunol. 2017; 198: 3005-3014https://doi.org/10.4049/jimmunol.1601693
        • Jaquiéry E.
        • Jilek S.
        • Schluep M.
        • et al.
        Intrathecal immune responses to EBV in early MS.
        Eur. J. Immunol. 2010; 40: 878-887https://doi.org/10.1002/eji.200939761
        • Johnson D.B.
        • McDonnell W.J.
        • Gonzalez-Ericsson P.I.
        • et al.
        A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis.
        Nat. Med. 2019; 25: 1243-1250https://doi.org/10.1038/s41591-019-0523-2
        • Lanz T.V.
        • Brewer R.C.
        • Ho P.P.
        • et al.
        Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM.
        Nature. 2022; 603: 321-327https://doi.org/10.1038/s41586-022-04432-7
        • Lerner A.
        • Benzvi C.
        Checkpoint inhibitors and induction of celiac disease-like condition.
        Biomedicines. 2022; 10: 609https://doi.org/10.3390/biomedicines10030609
        • Long H.M.
        • Meckiff B.J.
        • Taylor G.S.
        The T-cell response to Epstein-Barr virus - new tricks from an old dog.
        Front. Immunol. 2019; 10: 2193https://doi.org/10.3389/fimmu.2019.02193
        • Lossius A.
        • Vartdal F.
        • Holmøy T.
        Vitamin D sensitive EBNA-1 specific T cells in the cerebrospinal fluid of patients with multiple sclerosis.
        J. Neuroimmunol. 2011; 240-241: 87-96https://doi.org/10.1016/j.jneuroim.2011.09.011
        • Lünemann J.D.
        • Jelcić I.
        • Roberts S.
        • et al.
        EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2.
        J. Exp. Med. 2008; 205: 1763-1773https://doi.org/10.1084/jem.20072397
        • Magliozzi R.
        • Howell O.
        • Vora A.
        • et al.
        Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.
        Brain. 2007; 130: 1089-1104https://doi.org/10.1093/brain/awm038
        • Manenti S.
        • Orrico M.
        • Masciocchi S.
        • et al.
        PD-1/PD-L axis in neuroinflammation: new insights.
        Front. Neurol. 2022; 13877936https://doi.org/10.3389/fneur.2022.877936
        • Martin R.
        • Sospedra M.
        • Eiermann T.
        • Olsson T.
        Multiple sclerosis: doubling down on MHC.
        Trends Genet. 2021; 37: 784-797https://doi.org/10.1016/j.tig.2021.04.012
        • Moreno M.A.
        • Or-Geva N.
        • Aftab B.T.
        • et al.
        Molecular signature of Epstein-Barr virus infection in MS brain lesions.
        Neurol. Neuroimmunol. Neuroinflamm. 2018; 5: e466https://doi.org/10.1212/NXI.0000000000000466
        • Pender M.P.
        • Csurhes P.A.
        • Smith C.
        • et al.
        Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis.
        JCI Insight. 2018; 3e124714https://doi.org/10.1172/jci.insight.124714
        • Sellebjerg F.
        • Blinkenberg M.
        • Sorensen P.S.
        Anti-CD20 monoclonal antibodies for relapsing and progressive multiple sclerosis.
        CNS Drugs. 2020; 34: 269-280https://doi.org/10.1007/s40263-020-00704-w
        • Serafini B.
        • Rosicarelli B.
        • Aloisi F.
        • Stigliano E.
        Epstein-Barr virus in the central nervous system and cervical lymph node of a patient with primary progressive multiple sclerosis.
        J. Neuropathol. Exp. Neurol. 2014; 73: 729-731https://doi.org/10.1097/NEN.0000000000000082
        • Serafini B.
        • Rosicarelli B.
        • Franciotta D.
        • et al.
        Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain.
        J. Exp Med. 2007; 204: 2899-2912https://doi.org/10.1084/jem.20071030
        • Serafini B.
        • Rosicarelli B.
        • Veroni C.
        • et al.
        Epstein-Barr virus-specific CD8 T cells selectively infiltrate the brain in multiple sclerosis and interact locally with virus-infected cells: clue for a virus-driven immunopathological mechanism.
        J. Virol. 2019; 93: e00980-e00991https://doi.org/10.1128/JVI.00980-19
        • Serafini B.
        • Scorsi E.
        • Rosicarelli B.
        • et al.
        Massive intracerebral Epstein-Barr virus reactivation in lethal multiple sclerosis relapse after natalizumab withdrawal.
        J. Neuroimmunol. 2017; 307: 14-17https://doi.org/10.1016/j.jneuroim.2017.03.013
        • Serafini B.
        • Severa M.
        • Columba-Cabezas S.
        • et al.
        Epstein-barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation.
        J. Neuropathol. Exp. Neurol. 2010; 69: 677-693https://doi.org/10.1097/NEN.0b013e3181e332ec
        • Serafini B.
        • Zandee S.
        • Rosicarelli B.
        • et al.
        Epstein-Barr virus-associated immune reconstitution inflammatory syndrome as possible cause of fulminant multiple sclerosis relapse after natalizumab interruption.
        J. Neuroimmunol. 2018; 319: 9-12https://doi.org/10.1016/j.jneuroim.2018.03.011
        • Sollid L.M.
        Epstein-Barr virus as a driver of multiple sclerosis.
        Sci. Immunol. 2022; 7: eabo7799https://doi.org/10.1126/sciimmunol.abo7799
        • Sundqvist E.
        • Sundström P.
        • Lindén M.
        • et al.
        Epstein-Barr virus and multiple sclerosis: interaction with HLA.
        Genes Immun. 2012; 13: 14-20https://doi.org/10.1038/gene.2011.42
        • Tengvall K.
        • Huang J.
        • Hellström C.
        • et al.
        Molecular mimicry between anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk.
        Proc. Natl. Acad. Sci. U. S. A. 2019; 116: 16955-16960https://doi.org/10.1073/pnas.1902623116
        • van Nierop G.P.
        • Mautner J.
        • Mitterreiter J.G.
        • et al.
        Intrathecal CD8 T-cells of multiple sclerosis patients recognize lytic Epstein-Barr virus proteins.
        Mult. Scler. 2016; 22: 279-291https://doi.org/10.1177/1352458515588581
        • van Nierop G.P.
        • van Luijn M.M.
        • Michels S.S.
        • et al.
        Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patients.
        Acta Neuropathol. 2017; 134: 383-401https://doi.org/10.1007/s00401-017-1744-4
        • Veroni C.
        • Serafini B.
        • Rosicarelli B.
        • et al.
        Transcriptional profile and Epstein-Barr virus infection status of laser-cut immune infiltrates from the brain of patients with progressive multiple sclerosis.
        J. Neuroinflamm. 2018; 15: 18https://doi.org/10.1186/s12974-017-1049-5
        • Veroni C.
        • Aloisi F.
        The CD8 T cell-Epstein-Barr virus-B cell trialogue: a central issue in multiple sclerosis pathogenesis.
        Front. Immunol. 2021; 12665718https://doi.org/10.3389/fimmu.2021.665718
        • Wuest S.C.
        • Mexhitaj I.
        • Chai N.R.
        • et al.
        A complex role of herpes viruses in the disease process of multiple sclerosis.
        PLoS One. 2014; 9e105434https://doi.org/10.1371/journal.pone.0105434
        • Zdimerova H.
        • Murer A.
        • Engelmann C.
        • et al.
        Attenuated immune control of Epstein-Barr virus in humanized mice is associated with the multiple sclerosis risk factor HLA-DR15.
        Eur. J. Immunol. 2020; 51: 64-75https://doi.org/10.1002/eji.2020